ciclesonide (Alvesco) vs Fluticasone propionate/salmeterol (Advair HFA)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor · full Asthma pipeline

ciclesonide (Alvesco)

Marketed by Azurity Pharmaceuticals and partners

Approved in Asthmasmall molecule (corticosteroid)
Reliable signal

NCT00163397 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial comparing ciclesonide to budesonide, using lung function (FEV1) as the primary endpoint -- a regulator-accepted objective measure for asthma. The trial was designed as a non-inferiority comparison, and the prespecified margin test succeeded, meaning ciclesonide performed comparably to the active comparator on its primary measure.

Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.

Reported efficacy

Change from baseline to Week 16 in FEV1: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone (met)

Result source: NCT00174720

Fluticasone propionate/salmeterol (Advair HFA)

Marketed by GlaxoSmithKline

Approved in Asthmacombination (ICS + LABA)
Partial signal

NCT00448435 · Phase 3 · completed

The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.

Reported efficacy

Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)

Result source: NCT00448435

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointciclesonide (Alvesco)Fluticasone propionate/​salmeterol (Advair HFA)
Severe exacerbations, annualised rate—Not posted · NCT001747201.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
Trough FEV1, change—Not posted · NCT00174720—Not posted · NCT00646620
ACQ-5, change—Not posted · NCT00174720—Not posted · NCT00646620
OCS dose reduction—Not posted · NCT00174720—Not posted · NCT00646620

Severe exacerbations, annualised rate

ciclesonide (Alvesco)
—Not posted · NCT00174720
Fluticasone propionate/​salmeterol (Advair HFA)
1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699

Trough FEV1, change

ciclesonide (Alvesco)
—Not posted · NCT00174720
Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620

ACQ-5, change

ciclesonide (Alvesco)
—Not posted · NCT00174720
Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620

OCS dose reduction

ciclesonide (Alvesco)
—Not posted · NCT00174720
Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ciclesonide (Alvesco): 4 of 4 rows · Fluticasone propionate/salmeterol (Advair HFA): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricciclesonide (Alvesco)Fluticasone propionate/​salmeterol (Advair HFA)
Dropout rate
—a
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
11.8%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
—50/100 mcg/dayb
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
—50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
26.5%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
0%
NCT00449046 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
5.1%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
—50/100 mcg/dayb
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
—50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
3.3%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
—
NCT00449046 · Phase 3 · registry result, not featured evidence
Serious AEs
0%a
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
0.8%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
0%50/100 mcg/dayb
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
0%50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
4.6%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
—
NCT00449046 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
headaches/migraine 23.8% (placebo 22.7%)
respiratory infections 19% (placebo 18.2%)
bilateral otitis media 4.8% (placebo 0%)
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
50/100 mcg/dayb
upper respiratory tract inflammation 13.7%
nasopharyngitis 3.9%
stomatitis 3.9%
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
50/100 mcg/day
upper respiratory tract inflammation 34%
gastroenteritis 14%
nasopharyngitis 14%
NCT00448435 · Phase 3 · Asthma · phase 3
250/50 mcg BID
upper respiratory tract infection 20.3%
headache 18.3%
nasopharyngitis 17.6%
NCT00452699 · Phase 4 · registry result, not featured evidence
asthma 20%
bronchitis 20%
laryngopharyngitis 20%
NCT00449046 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ciclesonide (Alvesco)

Lower Leg Growth Velocity MM Wk 0.23 vs 0.33 Beconase and QVAR mm @ 52wk
absolute value · mm
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
0.23 vs 0.51 placebo mm @ 52wk
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
ACQ -0.76 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy

Fluticasone propionate/salmeterol (Advair HFA)

Morning PEF Change L/Min 14.3 vs 17.1 SLM + FP L50/100 mcg/day
absolute change · L
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Predicted 5.38% (n=48) vs 6.73% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Personal Best 5.01% (n=48) vs 6.46% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Evening PEF Change L/Min 16.3 vs 15.8 SLM + FP L/min50/100 mcg/day
absolute change · L/min
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Circadian Variation 0.06% (n=48) vs -0.08% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Symptom-Free Nights and 91.7% (n=48) vs 81.3% (n=48) SLM + FP @ 4wk50/100 mcg/day
absolute value · percentage points
After 4 Weeks of Treatment
NCT00448435 · Phase 3 · Asthma · phase 3
Rescue Medication-Free Nights 93.8% (n=48) vs 87.5% (n=48) SLM + FP @ 4wk50/100 mcg/day
responder rate · % of participants
After 4 Weeks of Treatment
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Change L/Min 3 L/min @ 30wk50/100 mcg/day
absolute change · L/min
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Predicted 1.46% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Personal Best 1.29% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Evening PEF Change L/Min 2.7 L/min @ 30wk50/100 mcg/day
absolute change · L/min
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Circadian Variation -0.37% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3

+ 12 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ciclesonide (Alvesco)'s landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape